DENVER, Colo. (247marketnews.com) -- SCIENTURE (NASDAQ:SCNX) is giving investors a fresh commercial catalyst as its FDA-approved Arbli oral suspension wins formulary placement at three leading U.S. pediatric academic medical centers and hospitals. The additions expand the product’s institutional footprint at a critical point in its rollout, while the company says wholesale orders have continued to increase sequentially. For a specialty pharmaceutical company focused on products addressing specific patient and healthcare-system needs, the latest formulary wins provide a tangible measure of expanding access for Arbli.
Arbli is a ready-to-use 10 mg/mL liquid formulation of losartan potassium, designed for patients who have difficulty swallowing conventional tablets or require flexible dosing. SCIENTURE says the product is particularly relevant in pediatric care because it eliminates the need for pharmacy compounding and provides consistent dosing in a room-temperature-stable formulation. Arbli is FDA-approved for hypertension in adults and children six years and older, as well as certain other cardiovascular and kidney-related indications.
The commercial opportunity is substantial. SCIENTURE cites IQVIA data showing a U.S. losartan market of approximately $219 million in annual sales and roughly 72 million prescriptions, creating a sizable established market for a differentiated liquid formulation. President and Co-CEO Narasimhan Mani said, “The commercial rollout of Arbli has continued to gain momentum, with wholesale orders increasing sequentially and adoption expanding across key healthcare channels.” He added that the company believes the combination of institutional adoption, rising wholesale orders and the size of the underlying market provides a foundation for continued growth.
The pediatric formulary wins could also become a springboard for additional institutional adoption. Executive Chairman and Co-CEO Shankar Hariharan said, “We believe this is just the beginning of the opportunity for Arbli within the pediatric hospital market.” SCIENTURE says it plans to continue pursuing hospital and institutional formularies while expanding payer coverage, pharmacy availability and nationwide distribution. The company also says Arbli has two issued USPTO patents listed in the FDA Orange Book.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.